Resolution Therapeutics strengthens its team with two new appointments
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The brand has added a range of exciting new products especially formulated for oily skin.
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Dr. Raman has succeeded Victoria Richon
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Subscribe To Our Newsletter & Stay Updated